P
Philipp Hadwiger
Researcher at Hoffmann-La Roche
Publications - 105
Citations - 7984
Philipp Hadwiger is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Small interfering RNA & RNA interference. The author has an hindex of 39, co-authored 104 publications receiving 7651 citations. Previous affiliations of Philipp Hadwiger include Hannover Medical School & University of Graz.
Papers
More filters
Journal ArticleDOI
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Jürgen Soutschek,Akin Akinc,Birgit Bramlage,Klaus Charisse,Rainer Constien,Mary Donoghue,Sayda Elbashir,Anke Geick,Philipp Hadwiger,Jens Harborth,Matthias John,Venkitasamy Kesavan,Gary Lavine,Rajendra K. Pandey,Timothy Racie,Kallanthottathil G. Rajeev,Ingo Röhl,Ivanka Toudjarska,Gang Wang,Silvio Wuschko,David Bumcrot,Victor Koteliansky,Stefan Limmer,Muthiah Manoharan,Hans-Peter Vornlocher +24 more
TL;DR: In this article, chemically modified short interfering RNAs (siRNAs) were used to silence an endogenous gene encoding apolipoprotein B (apoB) after intravenous injection in mice.
Journal ArticleDOI
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates
Maria Frank-Kamenetsky,Aldo Grefhorst,Norma N. Anderson,Timothy Racie,Birgit Bramlage,Akin Akinc,David Butler,Klaus Charisse,Robert Dorkin,Yupeng Fan,Christina Gamba-Vitalo,Philipp Hadwiger,Muthusamy Jayaraman,Matthias John,K. Narayanannair Jayaprakash,Martin Maier,Lubomir Nechev,Kallanthottathil G. Rajeev,Timothy Read,Ingo Röhl,Jürgen Soutschek,Pamela Tan,Jamie Wong,Gang Wang,Tracy Zimmermann,Antonin de Fougerolles,Hans-Peter Vornlocher,Robert Langer,Daniel G. Anderson,Muthiah Manoharan,Victor Koteliansky,Jay D. Horton,Kevin Fitzgerald +32 more
TL;DR: PCSK9 targeting with RNAi therapeutics as an approach to specifically lower LDLc is validated, paving the way for the development of PCSK9-lowering agents as a future strategy for treatment of hypercholesterolemia.
Journal ArticleDOI
Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma
Maria-del-Mar Inda,Rudy Bonavia,Akitake Mukasa,Akitake Mukasa,Yoshitaka Narita,Dinah W.Y. Sah,Scott R. VandenBerg,Cameron Brennan,Terrance Grant Johns,Robert Bachoo,Philipp Hadwiger,Pamela Tan,Ronald A. DePinho,Webster K. Cavenee,Frank B. Furnari +14 more
TL;DR: It is demonstrated that a paracrine mechanism driven by DeltaEGFR is the primary means for recruiting wtEGFR-expressing cells into accelerated proliferation in vivo, and support the view that a minor tumor cell population can potently drive accelerated growth of the entire tumor mass, and thereby actively maintain tumor cell heterogeneity within a tumor mass.
Journal ArticleDOI
Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells.
TL;DR: Two series of lipophilic siRNAs conjugated with derivatives of cholesterol, lithocholic acid or lauric acid are synthesized to improve the delivery of siRNA into human liver cells without transfection agents.
Journal ArticleDOI
Hepatocyte-targeted RNAi Therapeutics for the Treatment of Chronic Hepatitis B Virus Infection
Christine I. Wooddell,David B. Rozema,Markus Hossbach,Matthias John,Holly Hamilton,Qili Chu,Julia Hegge,Jason Klein,Darren H. Wakefield,Claudia E. Oropeza,Jochen Deckert,Ingo Roehl,Kerstin Jahn-Hofmann,Philipp Hadwiger,Hans-Peter Vornlocher,Alan McLachlan,David L. Lewis +16 more
TL;DR: It is shown that a single coinjection of NAG-MLP with potent chol-siRNAs targeting conserved HBV sequences resulted in multilog repression of viral RNA, proteins, and viral DNA with long duration of effect.